Log on / register
Feedback | Support | My details
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F
Breast Cancer Res 2005, 7:R436-43
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.
37%37%


 Research article    
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, Wallwiener D, Lane N, Solomayer E, Uhr J
Breast Cancer Research 2007, 9:R74 (26 October 2007)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles]
2.
37%37%


 Research    
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
DePrimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ
Journal of Translational Medicine 2007, 5:32 (2 July 2007)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles]
3.
37%37%


 Review    
HER-2 therapy. HER-2/neu diagnostics in breast cancer
Carney WP, Leitzel K, Ali S, Neumann R, Lipton A
Breast Cancer Research 2007, 9:207 (4 June 2007)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles]

You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2008 BioMed Central Ltd unless otherwise stated